The increasing drug prices in Europe

Vytenis Andriukaitis

Vytenis Andriukaitis, Member of the EC in charge of Health and Food Safety, and Carlos Moedas, Member of the EC in charge of Research, Science and Innovation, awarded the “Horizon Prize – Better Use of Antibiotics” and “The EU Health Awards for NGO’s fighting Antimicrobial Resistance” at a ceremony hold in Leuven. © European Union , 2017 / Source: EC – Audiovisual Service / Photo: Lukasz Kobus.

This article was written by one of our passionate readers, Mrs Rachel Everly. The opinions expressed within reflect only the writer’s views and not The European Sting’s position on the issue.

Rising drug prices have not been a recent issue, it has always been a part and parcel of the medical expenses. Not only is the United States suffering through a spike in the prices of medicines, but European medical bills have taken a toll for the worse as well. Prior to that, Europe had refrained from huge raises in the prices and until 2011, the selling price of many prescription pills had been steadily low.

Since most of the European nations are funding the healthcare systems on a government level, it is only understandable that they would want to keep a close track of the pharmaceutical industry. Due to this reason, the European Pharmaceutical companies are known to work on laws and regulations that restrict them from increasing the prices of the medicines for more than once a year. The price, profits, and comparison of the prices with the international market were always screened and assessed throughout the year without adjusting the prices.

In 2011, many European countries saw a gradual rise in multiple medicines and the rates have been rising ever since, without any restriction. This will affect many consumers and the fee structure of their individual health plans. To counter this problem, European Parliament’s environment Committee (ENVI) is favoring a non-legislative proposition that will strive for making these products more widespread in the European region. However, this must not be confused with an actual law being added in the region’s policies, as it is merely a resolution waiting to be approved by the authorities. With time, it may be considered and the European Union may only then choose to implement it.

The price of specific drugs has been a matter of huge concern for the public. Looking at the prices of those medicines in the previous years has shown an increase in prices for as much as over 1000%. Drugs that are used for leukemia patients have an increased price of 1225%, while tamoxifen, which is used primarily for breast cancer has risen by 1080% from 2011 to 2016. A chemotherapy drug has seen a spike of 1500% but later was fined for 5 million euros for an illegal increase in the price.

Charges of relatively new drugs that have little to no competition are also in the race for increasing their prices up to stupendous amounts. Multiple Sclerosis and Cancer treatment drugs are hiking due to lack of competition and insurance companies and pharmacy beneficiaries are losing against keeping these companies at bay.

The setting not only destabilizes the people who are insured but deeply affects the people who chose not to be insured or cannot afford healthcare. Previously, a person who could not have afforded to have themselves operated could find comfort in medicines. The same is not the case anymore and medical prescription drugs have become even more unattainable than before for many uninsured people out there. Seniors who have retired and do not have an insurance plan can also be looking at paying higher prices than they have previously been paying.

It has been debated for more than one year that the prices of the drugs do not represent the true cost of its production. It is concluded that the price of its manufacturing is far lower than the price label put on the product.  Most of these increments in prices have more to do with profits for these drug manufacturing companies and little to do with the increasing demands and lack of supply. To counter any research and development aspect of a new drug and decrease its cost, the patient-driven research is promoted. This means that the patient can sponsor the research and have the cure developed and tested.

Another speculation that has also been made is that due to the fact that they are only allowed to raise the costs once a year. This has made the marketers overly cautious and in order to withstand any possible demand and supply problem, or a price hike in the global market, they increase their rates by a huge percentage.

In order to provide a safer and more affordable plan for the healthcare system, the government, the people, and the drug manufacturers must work together. More and more efforts have been put on by EU health ministers in 2016 to warn the pharmaceuticals to lower the prices down as it has created a market that is highly unapproachable.

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Join the Hive!

Featured Stings

Resolving banks with depositors’ money?

Could entrepreneurship be the real cure against the side effects of Brexit?

IMF’s Lagarde indirectly cautioned Eurozone on deflation

Brexit talks started with a London handicap and Brussels’ sternness

AIESEC @ European Business Summit 2014: European Youth, Change Now Patiently

The eighth round of TTIP negotiations concludes in Brussels amid scepticism and new fears

Human Resources Information Systems Specialist Trainee – 2013

19th EU-China Summit: A historical advance in the Chino-European rapprochement

TTIP wins Merkel’s endorsement ahead of 2016 tough deadline

A Sting Exclusive: “Without climate, forget about peace!”, Swedish MEP Bodil Valero cautions from Brussels

Jo Cox’s murderer believed the ‘leave’ campaign leaders that the ‘remain’ vote is treason

Why the 33,000 staff European Commission did not have a real contingency plan for the refugee crisis?

MasterCard at European Business Summit 2015: A focus on innovation will drive inclusive economic growth for Europe

Macron has the deputies but not the people’s consent for his far reaching reforms

Tiny Iceland teaches the West how to treat bankers

A Sting Exclusive: “Doing ourselves a favour”, Vice President Dombrovskis underscores that this time growth has to come from within the EU

EU Banks still get subsidies from impoverished citizens

Commission: Raising the social issues that can make or break the monetary union

Draghi’s top new year resolution: Quantitative Easing

EU to spend €6 billion on youth employment and training futile schemes

The four top Americans who flew to Europe perplexed things about Trump’s intentions

Eurozone: Sovereign debt decreases for the first time since 2007

EU Commission says falling labour remuneration leads to deflation and damages growth prospects

More taxpayers’ money for the banks

Eurozone: A Sluggish economy offers no extra jobs

EU Parliament: Follow the fraudulent money and confiscate it

Climate Change: a challenge yet to be tackled in medical schools

Eurozone slowly but surely builds its Banking Union

The “Legend of the Sun” wishes you Happy Chinese New Year 2015 from Brussels

AIESEC @ European Business Summit 2015: The power of an individual and how we can awaken Europe’s Youth

Europe rethinking its severe austerity policies

Assembly of European Regions @ European Business Summit 2014: The European regions on the path to recovery

What UK and EU risk if Brexit “wins” these elections

Quality Education on the table at the European Parliament

Banks get trillions and the unemployed ECB’s love…

EU Parliament: It takes real banks to fight unemployment and recession

On Human Rights Day European Youth Forum calls for end to discrimination of young people

What the future holds for the EU – China relations?

Lessons from the Global Entrepreneurship Index

Poor Greeks, Irish and Spaniards still pay for the faults of German and French banks

EU citizens disenchanted with Economic and Monetary Union over rising poverty and high unemployment

The EU risks trade relations with China over the Tata hype about steel

Does the West play the Syrian game in Egypt?

International World Summit Award calls for outstanding digital applications with impact on society from 178 UN member states

Basel III rules relaxed: Banks got it all but become more prone to crisis

Will France vote for more or less Europe in the next presidential elections?

“They are trying to make improvements, but of course they are quite slow for my generation”, Vice President of JADE Victor Soto on another Sting Exclusive

EUREKA @ European Business Summit 2014: Innovation across borders – mobilising national R&D funds for transnational innovation in Europe

Who and why want the EU-US trade agreement here and now

Draghi’s ‘quasi’ announcement of a new era of more and cheaper money

The EU Spring Summit set to challenge austerity

Does the world have strong enough institutions to handle risks like Trump and Brexit?

On Grexit: Incompetence just launched the historic Ultimatum that could open “pandora’s box”

Macron’s Presidency: what the young generation’s expectations are

EU continues targeting on Chinese steel imports instead of the revival of its own economy

Industry 4.0: Championing Europe’s fourth industrial revolution

The EU Parliament and the ECB unknowingly or unwillingly fail to protect our financial assets

The 13th round of TTIP negotiations hits a wall of intense protests and growing concerns

Commission challenges Council over EU 2014 budget

Berlin cannot dictate anymore the terms for the enactment of the European Banking Union

More Stings?

Trackbacks

  1. […] The cost of new medical technologies and drugs remains the primary cause of the high rate of medical inflation: this is why a discussion at European level with the European Federation of Pharmaceutical Industries and Associations is still open: drug pricing is at the top of the bill. […]

  2. […] Il costo di nuove tecnologie e medicinali rimane la causa principale dell’aumento dei tassi di inflazione medica: questo è il motivo per cui a livello europeo è in corso una discussione con l’Associazione Europea delle Compagnie Farmaceutiche. Il punto principale dell’agenda è sempre quello: il continuo aumento dei medicinali. […]

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s